OBJECTIVES:

The rare bleeding disorder haemophilia A (HA) has substantial treatment burden. Recombinant FVIII (rFVII) therapies with extended half-lives (EHL) are available, offering reduced infusion frequency and resultant treatment burden versus standard half-life (SHL) products. While the EHL, damoctocog alfa pegol, has flexible dosing options, real-world data on utilization is scarce. This analysis examines treatment and utilization patterns of damoctocog alfa pegol in the real-world setting.

METHODS:

Data were collected from patients who switched to damoctocog alfa pegol in Germany in 2020, following the CHESS II (Cost of Haemophilia in Europe: a Socioeconomic Survey II) methodology, a European, retrospective, burden-of-illness study. Patients comprised of male non-inhibitor HA adults, treated prophylactically with damoctocog alfa pegol for at least 3 months in the real-world setting.

RESULTS:

Thirty-three HA patients met the inclusion criteria (3 [9%] moderate and 30 [91%] severe]. Thirty patients had consumption data available. Mean (SD) time since damoctocog alfa pegol switch was 32.1 (18.6) weeks and 24 (80%) patients were treated with SHL prior to switching. Post switch, weekly infusion frequency and IU consumption reduced in 93% and 83% of the sample, respectively. Mean (SD) utilization observed with damoctocog alfa pegol was 3,485 (684.2) IU/kg/year vs 5,040 (1,890.8) on previous treatment. Supplemental bleeding data were available in 22 patients; lower IU consumption and infusion frequency were reported in 91% and 100% of patients, respectively. Mean (SD) utilization in this sub-cohort was 3,530 (774.9) versus 5,591 (1,920.9) on previous treatment; 82% experienced lower annualised bleeding rate (ABR), 9% reported an increase, and 9% no change. Mean (SD; median) ABR reduced from 4.6 (4.4; 2.2) to 2.1 (1.8; 1.5).

CONCLUSIONS:

While limited in sample size, the results suggests damoctocog alfa pegol may reduce patient treatment burden and overall annual treatment utilization in the German real-world setting, while providing improved or equivalent bleeding outcomes.